

Special Issue

Genetics of Retinal and Vitreoretinal Diseases

Message from the Guest Editors

Mendelian retinal diseases occur at a frequency of about 1 in 2,000 individuals. The classification of these diseases includes not only stationary and progressive, syndromic and non-syndromic rod- or cone-dominated diseases but also generalized retinal degenerations and vitreoretinal disorders. The genetic landscape of these diseases provides essential information about the numerous biological and signaling pathways which are involved in disease onset and progression in addition to underlying pathophysiologic mechanisms. In addition to improvements in genetic testing, therapeutic interventions become increasingly realistic. Currently, five groups of therapeutic approaches to retinal diseases can be defined. The accumulation of our knowledge about genetic diseases of the retina and vitreous will hopefully lead to a more personalized care as well as treatment of an increasing number of patients in the future. This Special Issue of *Genes* is dedicated to the molecular basis, clinical consequences, and therapeutic developments in Mendelian diseases of the retina and vitreous.

Guest Editors

Prof. Dr. Wolfgang Berger

Institute of Medical Molecular Genetics, University of Zurich, 8006 Zurich, Switzerland

Prof. Dr. Christina Gerth-Kahlert

Department of Ophthalmology, University Hospital Zurich, 8091 Zurich, Switzerland

Deadline for manuscript submissions

closed (30 March 2022)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/71275

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))